Peter Vandenberghe
Overview
Explore the profile of Peter Vandenberghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
6885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passemiers A, Tuveri S, Jatsenko T, Vanderstichele A, Busschaert P, Coosemans A, et al.
Genome Biol
. 2025 Mar;
26(1):49.
PMID: 40055826
Cell-free DNA (cfDNA) is a rich source of biomarkers for various pathophysiological conditions. Preanalytical variables, such as the library preparation protocol or sequencing platform, are major confounders of cfDNA analysis....
2.
Pagliuca S, Malard F, Mooyaart J, Daskalakis M, Gabellier L, Yakoub-Agha I, et al.
Blood Rev
. 2025 Feb;
:101272.
PMID: 39986989
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional...
3.
Ieven T, Goossens J, Roosens W, Jonckheere A, Cremer J, Dilissen E, et al.
Front Immunol
. 2024 Dec;
15:1506034.
PMID: 39737168
Primary human mast cells (MC) obtained through culturing of blood-derived MC progenitors are the preferred model for the study of MRGPRX2- IgE-mediated MC activation. In order to assess the impact...
4.
Brijs J, Van Ham J, Dubois B, Sinap F, Vergote V, Dierickx D, et al.
Acta Clin Belg
. 2024 Oct;
79(4):276-284.
PMID: 39415456
Introduction: Large B-cell lymphomas (LBCL) are the most frequently aggressive B-cell non-Hodgkin lymphomas. Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has emerged as a new, powerful treatment for relapsed or...
5.
Stanley K, Jatsenko T, Tuveri S, Sudhakaran D, Lannoo L, Van Calsteren K, et al.
Nat Commun
. 2024 Mar;
15(1):2220.
PMID: 38472221
Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a...
6.
Alig S, Shahrokh Esfahani M, Garofalo A, Li M, Rossi C, Flerlage T, et al.
Nature
. 2023 Dec;
625(7996):778-787.
PMID: 38081297
The scarcity of malignant Hodgkin and Reed-Sternberg cells hampers tissue-based comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid biopsies show promise for molecular profiling of cHL due...
7.
Rengifo L, Smits S, Boeckx N, Michaux L, Vandenberghe P, Dewaele B
Genes Chromosomes Cancer
. 2023 Jun;
62(11):663-671.
PMID: 37293982
Copy number alterations (CNA) are powerful prognostic markers in myelodysplastic neoplasms (MDS) and are routinely analyzed by conventional cytogenetic analysis (CCA) on bone marrow (BM). Although CCA is still the...
8.
Van Thillo Q, Dewaele B, De Bie J, Michaux L, Devos T, Vandenberghe P
Br J Haematol
. 2023 May;
202(1):e7-e10.
PMID: 37129059
No abstract available.
9.
Messiaen J, Uyttebroeck A, Michaux L, Vandenberghe P, Boeckx N, Jacobs S
Mol Clin Oncol
. 2023 Feb;
18(3):18.
PMID: 36798463
Acute megakaryoblastic leukemia (AMKL) is a rare disease, occurring mostly in infants and young children. The chromosomal translocation t(1;22)(p13;q13), resulting in the RBM15-MKL1 fusion gene, is a recurrent and diagnostic...
10.
Provez L, Putteman T, Landfors M, Roels J, Reunes L, TSas S, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765607
T-cell lymphoblastic lymphoma (T-LBL) is a rare and aggressive lymphatic cancer, often diagnosed at a young age. Patients are treated with intensive chemotherapy, potentially followed by a hematopoietic stem cell...